TNF-α converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis

Journal of Neurology

Volumn 253, Issue 6, 2006, Pages 701-706

  Comabella, M ^a   Romera, C ^b   Camina M ^a   Perkal, H ^a   Moro, M A ^b   Leza, J C ^b   Lizasoain, I ^b   Castillo, M ^a   Montalban, X ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Interferon beta; Metalloproteinases; Multiple sclerosis; Tumor necrosis factor alpha

Indexed keywords

BETA INTERFERON; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY MECHANISM; RELAPSE; REMISSION; WESTERN BLOTTING;

ADAM PROTEINS; ADULT; BIOLOGICAL RESPONSE MODIFIERS; BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; LEUKOCYTES; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; STATISTICS; STATISTICS AS TOPIC;

EID: 33745567499     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-006-0090-6     Document Type: Article

References (30)

1. Compston A, Coles A (2002) Multiple sclerosis. Lancet 359:1221-1231
2. Leppert D, Ford J, Stabler G, Grygar C, Lienert C, Huber S, Miller KM, Hauser SL, Kappos L (1998) Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 121:2327-2334
3. Galboiz Y, Shapiro S, Lahat N, Rawashdeh H, Miller A (2001) Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary progressive multiple sclerosis patients. Ann Neurol 50:443-551
4. Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, Riccio P, Livrea P, Trojano M (2003) Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 136:46-53
5. Black RA (2002) Tumor necrosis factor-alpha converting enzyme. Int J Biochem Cell Biol 34:1-5
6. Moro MA, Hurtado O, Cardenas A, Romera C, Madrigal JLM, Fernandez-Tome P, Leza JC, Lorenzo P, Lizasoain I (2003) Expression and function of TAGE (TNF-alpha converting enzyme) in the central nervous system. Neurosignals 12:53-58
7. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA (1998) An essential role for ectodomain shedding in mammalian development. Science 282:1281-1284
8. Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA, Shows D, Peschon JJ, Black RA (2000) Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 275:14608-14614
9. Althoff K, Reddy P, Voltz N, Rose-John S, Mullberg J (2000) Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur J Biochem 267:2624-2631
10. Budagian V, Bulanova E, Orinska Z, Ludwig A, Rose-John S, Saftig P, Borden EC, Bulfone-Paus S (2004) Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17). J Biol Chem 279:40368-40375
11. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, Raines EW (2001) Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276:37993-38001
12. Condon TP, Flournoy S, Sawyer GJ, Baker BF, Kishimoto TK, Bennett CF (2001) ADAM17 but not ADAM10 mediates tumor necrosis factor-alpha and L-selectin shedding from leukocyte membranes. Antisense Nucleic Acid Drug Dev 11:107-116
13. Garton KJ, Gough PJ, Philalay J, Wille PT, Blobel CP, Whitehead RH, Dempsey PJ, Raines EW (2003) Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem 278:37459-37464
14. Sharief MK, Hentges R (1991) Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325:467-472
15. Bertolotto A, Malucchi S, Capobianco M, Manzardo E, Guastamacchia G, Milano E, Audano L, Mutani R (1999) Quantitative PCR reveals increased levels of tumor necrosis factor-alpha mRNA in peripheral blood mononuclear cells of multiple sclerosis patients during relapses. J Interferon Cytokine Res 19:575-581
16. Seifert T, Kieseier BC, Ropele S, Strasser-Fuchs S, Quehenberger F, Fazekas F, Hartung HP (2002) TACE mRNA expression in peripheral mononudear cells precedes new lesions on MRI in multiple sclerosis. Mult Scler 8:447-451
17. Kieseier BC, Pischel H, Neuen-Jacob E, Tourtellotte WW, Hartung HP (2003) ADAM-10 and ADAM-17 in the inflamed human CNS. Glia 42:398-405
18. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46:907-911
19. Montalban X (2004) Overview of European pilot study of interferon β-1b in primary progressive multiple sclerosis. Mult Scler 10:S62-S64
20. Hurtado O, Lizasoain I, Fernandez-Tome P, Moro MA, Alvarez-Barrientos A, Leza JC, Lorenzo P, et al. (2002) TACE/ADAM17-TNF-a pathway in rat cortical cultures after exposure to oxygen-glucose-deprivation or glutamate. J Cereb Blood Flow Metabolism 22:576-585
21. Schlöndorff J, Becherer JD, Blobel CP (2000) Intracellular maturation and localization of the tumour necrosis factor a convertase (TACE). Biochem J 347:131-138
22. Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi M, Montalban X, De Sa J (1997) Primary progressive multiple sclerosis. Brain 120:1085-1096
23. Revesz T, Kidd D, Thompson AJ, Barnard RO, McDonald WI (1994) A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 117:759-765
24. Giovannoni G, Lai M, Thorpe J, Kidd D, Chamoun V, Thompson AJ, Miller DH, Feldmann M, Thompson EJ (1997) Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology 48:1557-1565
25. Duran I, Martinez-Caceres EM, Rio J, Barbera N, Marzo ME, Montalban X (1999) Immunological profile of patients with primary progressive multiple sclerosis. Expression of adhesion molecules. Brain 122:2297-2307
26. Sastre-Garriga J, Comabella M, Brieva L, Rovira A, Tintore M, Montalban X (2004) Decreased MMP-9 production in primary progressive multiple sclerosis patients. Mult Scler 10:376-380
27. Vladic A, Horvat G, Vukadin S, Sucic Z, Simaga S (2002) Cerebrospinal fluid and serum protein levels of tumour necrosis factor-alpha (TNF-alpha) interleukin-6 (IL-6) and soluble interleukin-6 receptor (sIL-6R gp80) in multiple sclerosis patients. Cytokine 20:86-89
28. Rovaris M, Barnes D, Woodrofe N, du Boulay GH, Thorpe JW, Thompson AJ, McDonald WI, Miller DH (1996) Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups. J Neurol 243:536-542
29. Vikas V, Link H (1996) Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 45:322-333
30. Hollifield RD, Harbige LS, Pham-Dinh D, Sharief MK (2003) Evidence for cytokine dysregulation in multiple sclerosis: peripheral blood mononuclear cell production of pro-inflammatory and anti-inflammatory cytokines during relapse and remission. Autoimmunity 36:133-141